Costs of sequelae associated with invasive meningococcal disease: Findings from a US managed care population

Health Outcomes Research in Medicine

Volumn 2, Issue 4, 2011, Pages

  Karve, Sudeep ^a   Misurski, Derek ^b   Miller, Jacqueline ^b   Davis, Keith L ^a  

^a RTI HEALTH SOLUTIONS   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Economic burden; Health care utilization; Invasive meningococcal disease

Indexed keywords

MENINGOCOCCUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; COST; DISEASE ASSOCIATION; ECONOMIC EVALUATION; FEMALE; FOLLOW UP; HEALTH; HEALTH CARE UTILIZATION; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; INFANT; INVASIVE MENINGOCOCCAL DISEASE; MAJOR CLINICAL STUDY; MALE; MENINGOCOCCOSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; UNITED STATES;

EID: 84865797459     PISSN: None     EISSN: 18771319     Source Type: Journal    
DOI: 10.1016/j.ehrm.2011.08.001     Document Type: Article

References (44)

1. Bilukha OO, Rosenstein N. National Center for Infectious Diseases, Centers for Disease Control and Prevention. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2005; 54(RR-7):1-21.
2. Harrison LH. Epidemiological profile of meningococcal disease in the United States. Clin Infect Dis. 2010;50(Suppl 2):S37-S44.
3. O'Brien JA, Caro JJ, Getsios D. Managing meningococcal disease in the United States: hospital case characteristics and costs by age. Value Health. 2006;9(4):236-243. (Pubitemid 44126778)
4. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine. 2009;27(Suppl 2):B51-B63.
5. Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network. Neisseria meningitidis. 2008. [updated September 1, 2009]. Available at: http://www.cdc.gov/abcs/reports-findings/survreports/mening08.html. Last accessed April 4, 2011.
6. Cohn AC, MacNeil JR, Harrison LH, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis. 2010;50(2):184-191.
7. Boisier P, Nicolas P, Djibo S, et al. Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin Infect Dis. 2007;44(5):657-663.
8. Mutonga DM, Pimentel G, Muindi J, et al. Epidemiology and risk factors for serogroup X meningococcal meningitis during an outbreak in western Kenya, 2005-2006. Am J Trop Med Hyg. 2009;80(4):619-624.
9. Centers for Disease Control and Prevention. Progress toward elimination of Haemophilus influenzae type b invasive disease among infants and childrend United States, 1998-2000. MMWR Morb Mortal Wkly Rep. 2002;51(11): 234-237.
10. Lexau CA, Lynfield R, Danila R, et al. Active Bacterial Core Surveillance Team. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA. 2005;294(16):2043-2051. (Pubitemid 41539937)
11. Whitney CG, Farley MM, Hadler J, et al. Active Bacterial Core Surveillance of the Emerging Infections Program Network. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003;348(18):1737-1746. (Pubitemid 36514704)
12. Centers for Disease Control and Prevention. Licensure of a meningococcal conjugate vaccine (Menveo) and guidance for usedAdvisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep. 2010;59(9):273.
13. American Academy of Pediatrics. 2010 immunization schedules [updated February 1, 2011]. Available at: http://www.aap.org/immunization/ IZSchedule.html. Last accessed April 4, 2011.
14. Caro JJ, Möller J, Getsios D, et al. Invasive meningococcal disease epidemiology and control measures: a framework for evaluation. BMC Public Health. 2007;7:130.
15. Centers for Disease Control and Prevention. Vaccination coverage among adolescents aged 13-17 yearsdUnited States, 2007. MMWR Morb Mortal Wkly Rep. 2008;57(40):1100-1103.
16. Gardner P. Clinical practice. Prevention of meningococcal disease. N Engl J Med. 2006;355(14):1466-1473. (Pubitemid 44511561)
17. Borg J, Christie D, Coen PG, Booy R, Viner RM. Outcomes of meningococcal disease in adolescence: prospective, matched-cohort study. Pediatrics. 2009;123(3):e502-e509.
18. Erickson L,DeWals P.Complications and sequelae ofmeningococcal disease in Quebec, Canada, 1990-1994. Clin Infect Dis. 1998;26(5):1159-1164. (Pubitemid 28215481)
19. Erickson LJ, De Wals P, McMahon J, Heim S. Complications of meningococcal disease in college students. Clin Infect Dis. 2001;33(5):737-739. (Pubitemid 32762952)
20. Centers for Disease Control and Prevention. Active Bacterial Core Surveillance, Reports and Findings. Neisseria meningitidis. 1997-2008. [updated September 1, 2009]. Available at: http://www.cdc.gov/abcs/reportsfindings/ survreports/mening08.html. Last accessed April 4, 2011.
21. Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review andmeta-analysis. Lancet InfectDis. 2010;10(5):317-328.
22. Edmond K, Dieye Y, Griffiths UK, et al. Prospective cohort study of disabling sequelae and quality of life in children with bacterial meningitis in urban Senegal. Pediatr Infect Dis J. 2010;29(11):1023-1029.
23. Kane SV, Chao J, Mulani PM. Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn's disease patients. Adv Ther. 2009;26(10):936-946.
24. Mitra D, Davis KL, Beam C, Medjedovic J, Rustgi V. Treatment patterns and adherence among patients with chronic hepatitis C virus in a US managed care population. Value Health. 2010;13(4):479-486.
25. Wu EQ, Patel PA, Yu AP, et al. Disease-related and all-cause health care costs of elderly patients with gout. J Manag Care Pharm. 2008;14(2): 164-175. (Pubitemid 351453817)
26. Heyderman RS, Ben-Shlomo Y, Brennan CA, Somerset M. The incidence and mortality for meningococcal disease associated with area deprivation: an ecological study of hospital episode statistics. Arch Dis Child. 2004; 89(11):1064-1068.
27. Barquet N, Domingo P, Caylà JA, et al. Meningococcal disease in a large urban population (Barcelona, 1987-1992): predictors of dismal prognosis. Barcelona Meningococcal Disease Surveillance Group. Arch Intern Med. 1999;159(19):2329-2340. (Pubitemid 29501533)
28. Buysse CM, Raat H, Hazelzet JA, et al. Long-term health status in childhood survivors of meningococcal septic shock. Arch Pediatr Adolesc Med. 2008;162(11):1036-1041.
29. Buysse CM, Oranje AP, Zuidema E, et al. Long-term skin scarring and orthopaedic sequelae in survivors of meningococcal septic shock. Arch Dis Child. 2009;94(5):381-386.
30. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45: 613-619.
31. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130-1139. (Pubitemid 41587600)
32. Basu A, Manning WG. Issues for the next generation of health care cost analyses. Med Care. 2009;47(7 Suppl 1):S109-S114.
33. Fu AZ, Qiu Y, Radican L, Wells BJ. Health care and productivity costs associated with diabetic patients with macrovascular comorbid conditions. Diabetes Care. 2009;32(12):2187-2192.
34. Wedderburn RWM. Quasi-likelihood functions, generalized linear models, and the Gauss-Newton method. Biometrika. 1974;61:439-447.
35. Manning WG. The logged dependent variable, heteroscedasticity, and the retransformation problem. J Health Econ. 1998;17:283-295. (Pubitemid 28300217)
36. Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ. 2001;20:461-494. (Pubitemid 32515166)
37. Edwards MS, Baker CJ. Complications and sequelae of meningococcal infections in children. J Pediatr. 1981;99(4):540-545. (Pubitemid 12232084)
38. Naess A, Halstensen A, Nyland H, et al. Sequelae one year after meningococcal disease. Acta Neurol Scand. 1994;89(2):139-142. (Pubitemid 24095270)
39. Ramakrishnan M, Ulland AJ, Steinhardt LC, Moïsi JC, Were F, Levine OS. Sequelae due to bacterial meningitis among African children: a systematic literature review. BMC Med. 2009;7:47.
40. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med. 2001;344(18):1378-1388.
41. Tsolia MN, Theodoridou M, Tzanakaki G, et al. Invasive meningococcal disease in children in Greece: comparison of serogroup A disease with disease caused by other serogroups. Eur J Clin Microbiol Infect Dis. 2006; 25(7):449-456. (Pubitemid 44078597)
42. de Souza AL, de Oliveira AC, Romano CC, Sztajnbok J, Duarte AJ, Seguro AC. Interleukin-6 activation in ischemic stroke caused by Neisseria meningitidis serogroup C. Int J Cardiol. 2008;127(3):e160-e163. (Pubitemid 351885110)
43. Gironell A, Domingo P, Mancebo J, Coll P, Martí-Vilalta JL. Hemorrhagic stroke as a complication of bacterial meningitis in adults: report of three cases and review. Clin Infect Dis. 1995;21(6):1488-1491. (Pubitemid 26066647)
44. Ortega-Sanchez IR, Meltzer MI, Shepard C, et al. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States. Clin Infect Dis. 2008;46(1):1-13. (Pubitemid 351263552)